Patent ID: 6482840
Filing Date: 2002-11-19
Classification: C07D

Abstract:
or a pharmaceutically acceptable salt thereof wherein: R1 is1) hydrogen, 2) C1-10alkyl, 3) C2-10alkenyl, 4) C2-10alkynyl, wherein alkyl, alkenyl and alkynyl are optionally substituted with one to four substituents independently selected from Ra;R2 is 1) C1-10alkyl, 2) Ar1, 3) Ar1â€”C1-10alkyl, 4) Ar1â€”Ar2, 5) Ar1â€”Ar2â€”C1-10alkyl-, wherein the alkyl group is optionally substituted with one to four substituents selected from Ra, and Ar1 and Ar2 are optionally substituted with one to four substituents independently selected from Rb;R3 is 1) hydrogen, 2) C1-10alkyl, 3) C2-10alkenyl, 4) C2-10alkynyl, wherein alkyl, alkenyl and alkynyl are optionally substituted with one to four substituents independently selected from Ra;R5, R6, and R7 are independently selected from 1) hydroxy, 2) C1-10alkoxy, 3) C2-10alkenyl, 4) C2-10alkynyl, 5) cycloalkyl, 6) heterocyclyl, 7) aryl; 8) aryl C1-10alkyl, 9) heteroaryl; 10) heteroaryl C1-10alkyl, 11) â€”ORd, 12) â€”NO2, 13) halogen 14) â€”S(O)mRd, 15) â€”SRd, 16) â€”S(O)2ORd, 17) â€”S(O) mNRdRe, 18) â€”NRdRe, 19) â€”O(CRfRg)nNRdRe, 20) â€”C(O)Rd, 21) â€”CO2Rd, 22) â€”CO2(CRfRg)nCONRdRe, 23) â€”OC(O)Rd, 24) â€”CN, 25) â€”C(O)NRdRe, 26) â€”NRdC(O)Re, 27) â€”OC(O)NRdRe, 28) â€”NRdC(O)ORe, 29) â€”NRdC(O)NRdRe, 30) â€”CRd(Nâ€”ORe), 31) â€”CF3; or 32) â€”OCF3; wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally substituted with one to four substituents selected from a group independently selected from Rb; or R5 and R6 together with the atom or atoms to which they are attached form a fused or spirocyclic ring of 4 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;Ra is 1) hydrogen, 2) â€”ORd, 3) â€”NO2, 4) halogen 5) â€”S(O)mRd, 6) â€”SRd, 7) â€”S(O)2ORd, 8) â€”S(O)mNRdRe, 9) â€”NRdRe, 10) â€”O(CRfRg)nNRdRe, 11) â€”C(O)Rd, 12) â€”CO2Rd, 13) â€”CO2(CRfRg)nCONRdRe, 14) â€”OC(O)Rd, 15) â€”CN, 16) â€”C(O)NRdRe, 17) â€”NRdC(O)Re, 18) â€”OC(O)NRdRe, 19) â€”NRdC(O)ORe, 20) â€”NRdC(O)NRdRe, 21) â€”CRd(Nâ€”OR3), 22) CF3; or 23) â€”OCF3; Rb is 1) a group selected from Ra, 2) C1-10 alkyl, 3) C2-10 alkenyl, 4) C2-10 alkynyl, 5) cycloalkyl, 6) heterocyclyl, 7) aryl; 8) aryl C1-10alkyl, 9) heteroaryl; 10) heteroaryl C1-10 alkyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally substituted with one to four substituents selected from a group independently selected from Rc;Rc is 1) halogen, 2) â€”NRdRe, 3) carboxy, 4) cyano, 5) C1-4alkyl, 6) C1-4alkoxy, 7) aryl, 8) aryl C1-4alkyl, 9) heteroaryl, 10) hydroxy, 11) â€”CF3, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally substituted with one to four substituents selected from a group independently selected from Rc;Rd and Re are independently selected from hydrogen, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, Cy and Cy C1-10alkyl, wherein alkyl, alkenyl, alkynyl and Cy are optionally substituted with one to four substituents independently selected from Rc; or Rd and Re together with the atoms to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and nitrogen; Rf and Rg are independently selected from hydrogen, C1-10alkyl, Cy and Cyâ€”C1-10alkyl; or Rf and Rg together with the carbon to which they are attached form a ring of 4 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen; Cy is independently selected from cycloalkyl, heterocyclyl, aryl, or heteroaryl; Ar1 and Ar2 are independently selected from aryl and heteroaryl; m is an integer from 1 to 2; n is an integer from 1 to 10; r is an integer from 0 to 3; s is an integer from 1 to 3; r+s is an integer of 3; Y is 1) a bond, or 2) â€”CH2â€”.